Charles H. Large, PhD
(Chief Executive Officer)
Charles Large received his first degree and PhD from the University of Bristol and has more than 20 years of experience of drug discovery and development in the pharmaceutical industry. Before founding Autifony, he was Director of Molecular and Cellular Biology within the Neuroscience Centre of Excellence for Drug Discovery at GlaxoSmithKline, and has worked on programs focused on schizophrenia, Alzheimer's disease, epilepsy, bipolar disorder, and major depression. He is an expert on drugs that modulate voltage gated ion channels and their application to neurological and psychiatric disorders. He has built up a reputation in the field of sodium channel blocking drugs, and has collaborated widely with academic groups. He has authored over 50 papers, book chapters and patents relating to ion channel modulators.
Giuseppe S. Alvaro, PhD
(Founder and Head of Drug Discovery)
Giuseppe Alvaro was previously a Director and Chemistry Leader within the Neuroscience Centre of Excellence for Drug Discovery at GlaxoSmithKline. He obtained his PhD. in organic chemistry at the University of Bologna, where his research focused on the study of the reactivity and stereoselectivity of organometallic reagents for addition to chiral imines. Over the last 14 years, he has led programs focused on the identification of candidate molecules for CNS disorders and has acquired a deep understanding of the characteristics of small molecules essential for their development as pharmaceuticals. Dr Alvaro has an outstanding track record of identification of quality candidates that have successfully passed into the clinical phase. He is lead author and co-author of 55 articles and patents.
John Hutchison, BSc (Hons) PhD MBChB FRCP FFPM
(Chief Medical Officer)
John Hutchison is a UK-registered physician with over 25 years experience in the pharmaceutical industry, most recently as VP of Clinical Research at Pfizer Neusentis. Prior to that he was a Senior Partner at the Consultancy firm Transcrip Partners, and previously served as Chief Medical Officer and Development Director with Renovo and Vernalis. His early industry career was with Astra Charnwood where he was Director of Experimental Medicine. John's career has been heavily influenced by his Neuroscience background, having been awarded 1st Class Honours in Human Physiology and a PhD in Neurobiology by the University of Liverpool. His undergraduate and post-graduate medical training was conducted in Leicester, and he has been elected as a Fellow of both the Royal College of Physicians and the Faculty of Pharmaceutical Medicine. John has led the development of small and large molecule drugs in a variety of Central Nervous System, Pain and Sensory disorders, from early stage first in human studies through to global registration. John has a particular interest in translational medicine, and is a past member of the ABPI Experimental Medicine Committee.
Barbara Domayne-Hayman, DPhil.
(Chief Business Officer)
Barbara Domayne-Hayman brings a broad range of commercial experience, with many years of business development. Barbara was CEO of Stabilitech, a platform technology company, for over four years where she raised funding (including non-dilutive), and established twelve commercial collaborations. Previously she was Commercial Director at Arrow Therapeutics, an antiviral drug discovery and development company, until the company was acquired by AstraZeneca in 2007. Prior to Arrow, Barbara was Senior Business Development Manager at Celltech. She previously held senior international commercial strategy and marketing positions at Zeneca where she worked for over ten years. She holds a Sloan Fellowship from London Business School and has a BA and D.Phil in chemistry, from the University of Oxford.